Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules Optimi Health Receives Certificate of Analysis For GMP MDMA 40mg and 60mg MDMA Capsules.

Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer...